Mini-Tumor biobank could revolutionize cancer drug testing
NCT ID NCT05384184
First seen Nov 20, 2025 · Last updated Jun 19, 2026 · Updated 23 times
Summary
This completed study aimed to create a biobank of 'organoids'—tiny, 3D mini-tumors grown from liver cancer tissue. Researchers collected samples from 48 patients with colorectal cancer that spread to the liver or with primary liver cancer. The goal was to see if they could reliably grow and store these personalized organoids for future drug testing, potentially leading to more tailored cancer treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTASES AND HEPATOCELLULAR CARCINOMAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ap-HM hopital nord
Marseille, 13915, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this biobank could provide a powerful tool for testing cancer drugs on personalized mini-tumors, helping doctors choose the right treatment for each patient.
What could go wrong
This is a feasibility study with only 48 participants, focused on building the biobank, not testing treatments. The organoids may not fully predict real patient responses.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.